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Cannabinoids, cannabis and cannabis-based medicine for pain management: a 
systematic review of randomised controlled trials 
 
Abstract  
Cannabinoids, cannabis and cannabis-based medicines (CBM) are increasingly 
used to manage pain, with limited understanding of their efficacy and safety. We 
summarised efficacy and adverse events of these types of drugs for treating pain 
using randomised controlled trials: in people of any age, with any type of pain, and 
for any treatment duration. Primary outcomes were 30% and 50% reduction in pain 
intensity, and adverse events. We assessed risk of bias of included studies, and the 
overall quality of evidence using GRADE. Studies of <7 and >7 days treatment 
duration were analysed separately. We included 36 studies (7217 participants) 
delivering cannabinoids (8 studies), cannabis (6 studies), and CBM (22 studies); all 
had high and/or uncertain risk of bias. Evidence of benefit was found for cannabis <7 
days (risk difference 0.33, 95% confidence interval 0.20 to 0.46; 2 trials, 231 
patients, very low-quality evidence) and nabiximols >7 days (risk difference 0.06, 
95% confidence interval 0.01 to 0.12; 6 trials, 1484 patients, very low-quality 
evidence). No other beneficial effects were found for other types of cannabinoids, 
cannabis, or CBM in our primary analyses; 81% of subgroup analyses were 
negative. Cannabis, nabiximols, and delta-9-tetrahydrocannabinol had more adverse 
events than control. Studies in this field have unclear or high risk of bias, and 
outcomes had GRADE rating of low or very low-quality evidence. We have little 
confidence in the estimates of effect. The evidence neither supports nor refutes 
claims of efficacy and safety for cannabinoids, cannabis or CBM in the management 




There is no evidence from randomised controlled trials to support or reject the use of 
cannabinoids, cannabis and cannabis-based medicines in the management of pain.  
 
1.0. Introduction 
Pain is a common symptom of a wide variety of common conditions, and the 
primary reason most patients seek health care.[41] Globally, tension type headache 
is the primary cause of morbidity, with musculoskeletal and neuropathic pain also 
common.[58] The incidence of chronic pain is routinely estimated to be between 11-
40% of the population, with as many as 10% reporting high impact pain.[9; 18] 
Chronic pain has a larger impact on quality of life than other common chronic 
conditions,[70] and there is a graded increase in mortality as pain severity increases 
in older adults, especially for patients who report walking disability [66; 67]. 
Pharmacological treatments can provide considerable improvements, 
including reduced pain intensity and increased function. However, this benefit is 
limited to a minority of patients,[45] or those reporting acute pain after surgery and 
cancer pain.[46] These findings all relate to adult data. For children and adolescents 
there are little data of any kind to guide practice.[13; 14] 
Cannabis plant material typically contains over 450 different compounds, with 
over 100 classified as phytocannabinoids. The two phytocannabinoids that have 
been most studied to-date in the context of medical research are delta 9-
tetrahydrocannabinol (THC, the main psychoactive constituent), and cannabidiol 
(CBD). A large body of pre-clinical data provides evidence for antinociceptive effects 
of cannabinoids and modulators of the body’s own endogenous cannabinoids 
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(endocannabinoids).[55; 71; 79]  The analgesic effects of THC are mediated 
primarily via agonism of cannabinoid1 (CB1) and cannabinoid2 (CB2) receptors, with 
the former being chiefly responsible for its psychoactive effects.  In contrast, CBD 
does not activate CB1 or CB2 receptors and appears to have a complex 
pharmacology with activity at a number of different targets which include, but are not 
limited to: 5-HT1A receptor agonism, negative allosteric modulation of CB1, GPR55 
antagonism, TRPV1 activation, PPARγ activation, reuptake inhibition [e.g. 
anandamide, adenosine]).[7; 31; 36; 56; 60; 61; 73] Table 1 (adapted from Hauser et 
al., (2018) [27]) provides a summary of current terminology, definitions and typical 
products. 
There is considerable research interest in the use of cannabinoids, medicinal 
cannabis and cannabis-based medicines (CBM), including for pain. In our recent 
overview review we found 57 reviews of which 49 were very low or low- quality. 
There is a need for a high-quality systematic review summarising the evidence. 
In 2018 the International Association for Study of Pain (IASP) established a 
Presidential Task Force on Cannabis and Cannabinoid Analgesia to investigate the 
use of cannabis and cannabinoid based medicinal products for pain management. 
This review is part of the Task Force and aimed to provide a comprehensive 
summary of the evidence from primary randomised controlled trials (RCTs) of 
cannabinoids, cannabis and CBM in clinical acute and chronic pain management, 
across the lifespan. We used randomized trials because they typically provide the 
least biased estimate for treatment efficacy. In this review, we (1) provide estimates 
of the efficacy and adverse events from trial data, and (2) provide an assessment of 




2.1. Protocol Registration  
We registered the protocol for this systematic review [19] and on Prospero 
(ID: CRD42019124714). We followed the Preferred Reporting Items for Systematic 
Review and Meta-Analysis Protocols.[42] The aims, rationale, and methods are 
identical to those set out in the protocol. Where we deviated from the protocol we 
have noted this. This review was conducted alongside an overview review [47] and 
as part of the IASP Presidential Task Force on Cannabis and Cannabinoid 
Analgesia. 
 
2.2. Type of participants  
We included people with acute or chronic pain. Chronic pain is defined as 
continuous or recurrent pain lasting for longer than three months. Acute or chronic 
pain includes, but was not limited to, the following conditions: abdominal pain, cancer 
pain, headache, migraine, acute or chronic neuropathic pain, acute or chronic 
musculoskeletal pain, pelvic pain, menstrual pain, acute postoperative pain, or any 
other form of pain. We included people with pain across the lifespan (including 
children). However, we excluded trials of people undergoing experimental pain 
procedures. We only included trials that retained 30 participants/arm at post-
treatment or more. Trials that include smaller sample sizes are more likely to 
produce larger effects.[10; 72] However, for transparency, we have included a 





2.3. Types of interventions and comparators 
We included any type of cannabinoid product, natural or synthetic, delivered 
by any route of administration. We included any control, including placebo or active 
pain therapy, pharmacological or non-pharmacological. Trials that delivered 
cannabinoids, cannabis or CBM in addition to other drugs were also included. We 
only included trials that had the intention of decreasing self-reported pain intensity in 
participants.  
 
2.4. Types of outcomes 
We extracted the following primary and secondary outcomes: 
 
2.4.1. Primary outcomes  
1. The proportion of people with at least 30% pain intensity reduction/ moderate 
improvement defined by IMMPACT;[12] 
2. The proportion of people with at least 50% pain intensity reduction/ substantial 
improvement defined by IMMPACT.[12] 
 
2.4.2. Secondary outcomes 
1. Continuous assessments of pain intensity (e.g., using a numerical rating scale 
or visual analogue scale); 
2. The proportion of people who experienced a decrease in pain from 
moderate/severe to mild; 
3. Disability or physical functioning; 
4. Emotional functioning (e.g., anxiety, depression); 
5. Carer Global Impression of Change; 
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6. Quality of life as defined by validated scales; 
7. The number of adverse events. Adverse events will include measures of 
harm, including withdrawal due to serious adverse events, withdrawal 
because of adverse events, patients reporting any adverse event, and 
particular adverse events (especially CNS and cardiovascular adverse 
events). Following the PRISMA Harms Checklist, we will describe how 
adverse events were addressed, how they were reported, and over what time 
period the harm was experienced;[82] 
8. Requirement for rescue analgesia; 
9. Sleep duration and quality; 
10. Onset and duration of analgesic effects (when relevant in acute pain trials). 
 
2.5. Search method and study selection  
We searched the literature using a staged approach. 1) We searched 
PubMed, EMBASE, and CENTRAL to April 2019 (see Appendix 1 for search 
strategies). We conducted a targeted search for RCTs in this area in January 2020 
for any new studies. Two authors independently sifted the titles and abstracts 
identified in the database search. A third author resolved any disagreements. We did 
not restrict the searches on language or date. 2) We searched online trial registry 
databases including clinicaltrials.gov, EudracT. 3) We searched the trials of 
systematic reviews included in the overview review.[47] 4) We conducted reference 
and citation searches of included trials to search for further trials. 
We included any peer reviewed publication or online trial registration that 
investigated the therapeutic effects of any cannabinoid preparation, given by any 
route of administration, for relief of pain, compared with placebo or a different active 
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treatment. We did not include trials based on the measures they reported. We did 
not seek other types of grey literature (e.g., unpublished dissertations) or conference 
abstracts.  
 
2.6. Data extraction 
Two authors independently extracted data from included trials. A third author 
resolved disagreements. We extracted the following data from each study:  
1. Study characteristics, e.g., design, participants enrolled, age, sex, pain 
condition, and inclusion/exclusion criteria. 
2. Intervention and comparator characteristics, e.g., type of cannabinoid, dose, 
route of administration, comparator. 
3. Outcomes – we extracted any outcomes listed in the primary and secondary 
outcomes of this review. We extracted outcomes at short-term (between up to 
7 days post-administration) and long-term (greater than or equal to 7 days 
post-administration).  
 
2.7. Risk of bias 
Two authors independently assessed the risk of bias of included studies using 
the Cochrane risk of bias tool [29] and a third author resolved disagreements. We 
assessed the following risk of bias categories, making judgements using the 
following criteria.1  
 
1 Please note that this section uses suggested wording from the Cochrane Pain, 
Palliative, and Supportive Care Review Group template, which are used in a number 
of Cochrane reviews (including, but not limited to [44, 75] and is unaltered from the 
original.  
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• Random sequence generation (checking for possible selection bias). We 
assessed the method used to generate the allocation sequence as: low risk of 
bias (any truly random process, e.g. random number table; computer random 
number generator); unclear risk of bias (insufficient detail about the method of 
randomisation to be able to judge the generation as 'low' or 'high' risk of bias). 
Studies using a non-random process (e.g. odd or even date of birth; hospital 
or clinic record number) were excluded. 
• Allocation concealment (checking for possible selection bias). The method 
used to conceal allocation to interventions prior to assignment determines 
whether intervention allocation could have been foreseen in advance of, or 
during recruitment, or changed after assignment. We assessed the methods 
as: low risk of bias (e.g. telephone or central randomisation; consecutively 
numbered sealed opaque envelopes); unclear risk of bias (insufficient detail 
about the method of randomisation to be able to judge the generation as 'low' 
or 'high' risk of bias). Studies that do not conceal allocation (e.g. open list) 
were excluded. 
• Blinding of participants and personnel (checking for possible performance 
bias). We assessed the methods used to blind study participants and 
personnel from knowledge of which intervention a participant received. We 
assessed methods as: low risk of bias (no blinding or incomplete blinding, but 
the review authors judge that the outcome was not likely to be influenced by 
lack of blinding, or blinding of participants and key study personnel ensured, 
and unlikely that the blinding could have been broken); unclear risk of bias 
(insufficient detail about the method of blinding to be able to judge the 
generation as 'low' or 'high' risk of bias, or the study does not address this 
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outcome), or high risk of bias (no blinding or incomplete blinding, and the 
outcome was likely to be influenced by lack of blinding, or blinding of key 
study participants and personnel attempted, but likely that the blinding could 
have been broken, and the outcome was likely to be influenced by lack of 
blinding).  
• Blinding of outcome assessment (checking for possible detection bias). We 
assessed the methods used to blind study participants and outcome 
assessors from knowledge of which intervention a participant received. We 
assessed the methods as: low risk of bias (no blinding of outcome 
assessment, but the review authors judge that the outcome measurement 
was not likely to be influenced by lack of blinding, or blinding of outcome 
assessment ensured, and unlikely that the blinding could have been broken); 
unclear risk of bias (insufficient detail about the method of blinding to be able 
to judge the generation as 'low' or 'high' risk of bias, or the study does not 
address this); high risk of bias (no blinding of outcome assessment, and the 
outcome measurement was likely to be influenced by lack of blinding, 
or blinding of outcome assessment, but likely that the blinding could have 
been broken, and the outcome measurement was likely to be influenced by 
lack of blinding).  
• Incomplete outcome data (checking for possible attrition bias due to the 
amount, nature and handling of incomplete outcome data). We assessed the 
methods used to deal with incomplete data as: low risk (no missing outcome 
data; reasons for missing outcome data unlikely to be related to true outcome 
(for survival data, censoring unlikely to be introducing bias); missing outcome 
data balanced in numbers across intervention groups, with similar reasons for 
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missing data across groups; missing data have been imputed using 'baseline 
observation carried forward’ analysis); unclear risk of bias (insufficient 
reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ 
(e.g. number randomised not stated, no reasons for missing data provided, 
or the study did not address this outcome);  high risk of bias (reason for 
missing outcome data is likely to be related to true outcome, with either 
imbalance in numbers or reasons for missing data across intervention 
groups; ‘as-treated’ analysis done with substantial departure of the 
intervention received from that assigned at randomisation; potentially 
inappropriate application of simple imputation). 
• Selective reporting (checking for reporting bias). We assessed reporting 
biases due to selective outcome reporting. We judged studies as: low risk of 
bias (the study protocol is available and all of the study’s pre-specified 
(primary and secondary) outcomes that are of interest in the review have 
been reported in the pre-specified way; the study protocol is not available but 
it is clear that the published reports include all expected outcomes, including 
those that were pre-specified (convincing text of this nature may be 
uncommon); unclear risk of bias (insufficient information available to permit a 
judgement of ‘low risk’ or ‘high risk’); high risk of bias (not all of the study’s 
pre-specified primary outcomes have been reported; one or more primary 
outcomes have been reported using measurements, analysis methods or 
subsets of the data (e.g. subscales) that were not pre-specified; one or more 
reported primary outcomes were not pre-specified (unless clear justification 
for their reporting is provided, such as an unexpected adverse effect); one or 
more outcomes of interest in the review have been reported incompletely so 
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that they cannot be entered in a meta-analysis; the study report failed to 
include results for a key outcome that would be expected to have been 
reported for such a study). 
• Size (checking for possible biases confounded by small size). We assessed 
size of study as low risk of bias (>200 participants/arm); unclear risk of bias 
(50-199 participants/arm); or high risk of bias (<50 participants/arm).  
 
2.8. Quality of the evidence2  
We assessed the quality of the evidence using GRADE. Two review authors 
rated the quality of each outcome. The GRADE approach uses five considerations 
(study limitations, unexplained heterogeneity and inconsistency of effect, 
imprecision, indirectness, and publication bias) to assess the quality of the body of 
evidence for each outcome. The GRADE system uses the following criteria for 
assigning grade of evidence: 
• High: we are very confident that the true effect lies close to that of the estimate 
of the effect; 
• Moderate: we are moderately confident in the effect estimate; the true effect is 
likely to be close to the estimate of effect, but there is a possibility that it is 
substantially different; 
• Low: our confidence in the effect estimate is limited; the true effect may be 
substantially different from the estimate of the effect; 
 
2 Please note that this section uses suggested wording from the Cochrane 
Pain, Palliative, and Supportive Care review group template, which are used in a 
number of Cochrane reviews (including, but not limited to [44, 75] and is unaltered 
from the original.  
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• Very low: we have very little confidence in the effect estimate; the true effect is 
likely to be substantially different from the estimate of effect. 
Factors that may decrease the quality level of a body of evidence are: 
• Limitations in the design and implementation of available studies suggesting 
high likelihood of bias; 
• Indirectness of evidence (indirect population, intervention, control, outcomes); 
• Unexplained heterogeneity or inconsistency of results (including problems 
with subgroup analyses); 
• Imprecision of results (wide confidence intervals); 
• High probability of publication bias. 
We decreased the grade rating by one (- 1) level (from high to moderate quality of 
evidence), two (- 2) levels (to low-quality evidence) or three (-3) levels (to very-low 
quality of evidence). Outcomes can be downgraded a maximum of three levels using 
the following criteria:  
• Serious (-1) or very serious (- 2) study limitations. 
• Some (- 1) or considerable (-2) inconsistency of results. 
• Some (-1) or considerable (- 2) uncertainty about directness. 
• Some (-1) or considerable (-2) imprecision. 
• Some (-1) or considerable (-2) probability of reporting bias. 
There may be circumstances where the overall rating for a particular outcome needs 
to be adjusted as recommended by GRADE guidelines [24]. Examples might be 
where there are so few participants that the results are highly susceptible to the 
random play of chance, or if studies use last observation carried forward (LOCF) 
imputation in circumstances where there are substantial differences in adverse event 
withdrawals. In circumstances such as this there would be little confidence in the 
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result, which would be downgraded three levels, to very low quality. In circumstances 
where there are no data reported, we reported the level of evidence as very low 
quality.[23] 
 
2.9. ‘Summary of findings’ tables  
We planned to present two main ‘summary of findings’ tables; cannabis vs. 
control, and CBM (to include individual cannabinoids) vs. control. We planned to 
include the following seven outcomes; 50% pain reduction, 30% pain reduction, 
adverse events, serious adverse events, physical functioning, emotional functioning, 
and sleep. We rated the quality of evidence for all analyses.  
       
2.10. Data synthesis  
We combined data in meta-analyses where sufficient data were available 
using Revman 5.0. We used mean differences for continuous outcomes, and risk 
difference for dichotomous outcomes. We calculated number needed to treat to 
benefit (NNTB) where we were able. Heterogeneity was interpreted following the 
Cochrane Handbook.[30] Adverse events were entered into meta-analyses and 
calculated using risk differences and 95% confidence intervals. Where possible, we 
described any assessment of possible causality of adverse events.  
We conducted comparisons of cannabis vs. control, and CBM (including 
individual cannabinoids) vs. control, for each of our named outcomes to determine 
efficacy. We conducted four primary analyses, which included all trials, conducted 
with a subgroup analysis by drug type, at two time-points:   
1. Cannabis vs. control at short-term follow-up (up to 7 days treatment duration) 
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2. Cannabis vs. control at long-term follow-up (greater than or equal to 7 days 
treatment duration) 
3. CBM vs. control at short-term follow-up (up to 7 days treatment duration) 
4. CBM vs. control at long-term follow-up (greater than or equal to 7 days 
treatment duration).  
We planned to conduct sensitivity analyses where appropriate to investigate the 
impact of risk of bias and study quality. 
 
2.10.1. Subgroup analyses 
In addition, where enough data were available, we conducted the following 
subgroup analyses at two time-points outlined above: 
1. Age of participants (2-10 years, 11-17 years, 18-64 years, over 65 
years); 
2. Type of comparator; 
3. Route of administration; 
4. Dose of treatment; 
5. Type of pain experienced (acute, neuropathic pain, fibromyalgia, 
musculoskeletal pain, headache/migraine, etc.). 
6. Cannabis or CBM administered adjunctively versus non-adjunctively to 
other medicines. 
 
3.0.  Results 
We found 8608 abstracts in the database search and 130 abstracts from other 
searches. After duplicates were removed, we sifted 7080 abstracts (Figure 1). We 
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pulled 193 full texts and subsequently excluded 129 full texts, with 36 trials meeting 
our inclusion criteria.  
Of the 129 excluded studies, we excluded 39 studies that included fewer than 
30 participants post-treatment, 27 trials that did not include people with a pain 
condition, 24 studies that did not assess pain as an outcome, 21 conference 
abstracts, two follow-up studies that were single arm, and one experimental pain 
study (see Appendix 2). Fifteen trials are awaiting classification; of these, three are 
completed, five are not yet recruiting, three are recruiting, one is ongoing, one is 
unknown, and two prematurely ended (no results). (see Appendix 3).  
Appendix 4 describes the 39 excluded studies due to small size alone.  
 
3.1.  Included studies 
The 36 completed RCTs meeting our inclusion criteria included four trial 
registrations without associated journal manuscripts. Across all studies, 7217 
participants were randomized to trial arms and 6149 completed treatment giving an 
average of 14.4% attrition (0-33%). In 34 trials that reported sex, females (n = 3691) 
outnumbered males (3163). The average age of participants was 51 years (SD = 
11). We did not find any trials including children or adolescents <18 years of age.  
We found trials that treated people with neuropathic pain (n = 13), cancer (n = 
6), acute pain after surgery (n = 4), multiple sclerosis (MS) (n = 10), and one each 
treated people with chronic prostatitis/chronic pelvic pain, carpal tunnel syndrome, 
and back pain.  
Twenty-three trials had two arms, eight used three arms, two four arms, two 
five arms, and one six arms.  
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Trials delivered a treatment arm of nabiximols (n = 17), cannabis (n = 6), THC 
(n = 4; varying doses), palmitoylethanolamide (PEA; n = 3), FAAH inhibitors (n = 2; 
ASP3652, ASP8477), Dronabinol (n = 2), Nabilone (n = 2), cannabinoid receptor 
agonist (n = 2; AZD1940, GW842166), THC congener (n = 1; benzopyran peridine). 
A summary of trial characteristics are shown in Table 2. A more extensive 
description can be found in Appendix 9 and 10.   
Thirty trials used only a placebo control arm. Two studies used active controls 
of dihydrocodeine or piritramide. Four trials delivered naproxen, ibuprofen, or 
codeine in addition to placebo. Most studies delivering treatments to participants with 
chronic pain did so in addition to on-going analgesics.  
 
3.2. Risk of bias  
Risk of bias judgments for each study are shown in Figures 2 & 3 and 
described in Appendix 5.  
Random sequence generation (checking for possible selection bias). We 
judged 17 studies to be at low risk of bias for random sequence generation, and we 
judged the remaining studies as unclear risk of bias as they did not provide a method 
of randomisation.  
Allocation concealment (checking for possible selection bias). Eleven studies 
described a convincing method of allocation concealment and were rated as low risk 
of bias. The remaining studies did not describe how they concealed allocation and 
therefore we rated them unclear.  
Blinding of participants and personnel (checking for possible performance 
bias). We found 18 studies provided a method of blinding participants and personnel 
in the manuscript, which we rated as low risk of bias. The remaining studies did not 
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provide a clear statement of blinding, and therefore we rated these as unclear risk of 
bias.  
Blinding of outcome assessment (checking for possible detection bias). We 
rated 17 studies as low risk of bias who stated a clear method of blinding outcome 
assessors in studies. We rated the remaining studies as unclear, as they did not 
provide a clear method of blinding their outcome assessors.  
Incomplete outcome data (checking for possible attrition bias due to the 
amount, nature and handling of incomplete outcome data). We rated 10 studies as 
low risk of bias for incomplete outcome data. These studies either did not report 
many dropouts during treatment or used baseline observation carried forwards. 
Twenty studies did not clearly report their data imputation method and therefore we 
rated these as unclear risks of bias. The remaining six studies used last observation 
carried forwards and therefore, we rated these studies as high risk of bias.  
Selective reporting (checking for reporting bias). We found 12 studies pre-
registered a protocol and reported all pre-specified outcomes in the manuscript. We 
found nine studies did not pre-register the protocol and rated these as unclear risk of 
bias. We rated 15 studies as high risk of bias; these studies pre-registered their 
protocol but did not report all outcomes in the manuscript or included additional 
outcomes in the manuscript, or have not published their results in a scientific journal.  
Size. We found two studies had more than 200 participants/arm and therefore 
rated these as low risk of bias. A further 14 studies included between 50-200 
participants/arm and judged these to be unclear risk of bias. We judged the 




3.3. Treatment efficacy 
 We found very few post-treatment means and standard deviations in 
treatment manuscripts and clinical registries to enter into analyses. When we 
requested data from authors, few replied. The authors who did respond referred us 
to the pharmaceutical companies, who referred us to the manuscript and clinical 
registry, and did not provide additional data not listed in either place. Most 
extractable data reported mean change from baseline.  
 We were unable to conduct the intended subgroup analysis due to lack of 
variability in the included studies. We also did not conduct sensitivity analyses by risk 
of bias, as most studies were either unclear or high risk of bias. Therefore, we 
included subgroup analyses of drug type in the primary comparisons, and also by 
pain condition.   
We present efficacy outcomes of 30% and 50% reduction in pain intensity, 
and post-treatment means and standard deviations. Due to the lack of transparency 
caused by the inaccessibility of means and standard deviation data we decided post-
protocol to also extract change from baseline means and standard deviation. 
Although this is selective reporting from the primary investigator, our reporting of 
them provides greater transparency. We report the change from baseline scores for 
pain below, and change from baseline means for secondary outcomes are fully 
described with forest plots in Appendices 6 and 7.   
We report adverse events for cannabis and individual CBM, but do not report 
adverse events by treatment length.   
We planned to present two main ‘summary of findings’ tables; cannabis vs. 
control, and CBM (to include individual cannabinoids) vs. control. However, due to 
 19 
the lack of data for cannabis and most CBM, we only present one summary of 
findings table for nabiximols (Table 3). 
 
3.3.1 Cannabis vs. control at short-term follow-up (up to 7 days treatment 
duration) 
Three trials by one author group evaluated the effects of inhaled or vaporised 
cannabis on chronic neuropathic pain in single dose experiments lasting one day or 
less.[76-78] The studies were all three-arm trials, comparing different doses of THC 
content to placebo. One further study conducted a single dose crossover trial 
including cannabis and placebo in participants with multiple sclerosis.[6] Only one 
trial included participants with a minimum pain intensity score.[78] 
Pain: Two trials (231 patients) reported a beneficial effect of cannabis at 
reducing pain intensity by at least 30% (Risk difference (RD) 0.33, 95% confidence 
intervals (CI) 0.20 to 0.46; very low-quality, Analysis 1.1).[76; 78] An earlier study by 
the same group that met inclusion also indicated short term antinociceptive effects of 
inhaled cannabis.[77] This would be equivalent to an NNTB of 3; the number of 
patients in nil effect trials required to reduce the effect to a clinically irrelevant NNTB 
of 10 would be 773, and to an NNTB of 20 would be 1876. 
These two studies showed a short-term analgesic effect for inhaled cannabis 
after single doses. The size of effect (33% more patients with at least 30% pain 
intensity reduction) was of potential clinical significance. 
One study reported continuous pain intensity post-treatment and so could not 
be combined in an analysis.[6] There was no difference between treatment and 
control for pain intensity.  
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Secondary outcomes: One study presented extractable data for emotional 
functioning.[6] However, there was no difference between groups post-treatment. 
Despite other outcomes assessed, we could not extract any data from the 
manuscripts or clinical trial.gov registration.  
We downgraded GRADE ratings on all outcomes for this comparison to very 
low due to the small number of participants contributing to analyses, meaning we 
have very little confidence in the effect estimate; the true effect is likely to be 
substantially different from the estimate of effect.  
 
3.3.2 Cannabis vs. control at long-term follow-up (greater than or equal to 7 
days treatment duration) 
 Two studies by one author group delivered cannabis treatment compared to 
placebo control over a 12-15 week treatment period.[80; 81] Oral capsules were 
delivered to participants with multiple sclerosis, and neither study defined a minimum 
pain intensity as part of the inclusion criteria. We could not combine any data and 
therefore no meta-analyses are presented.  
Pain: One study with 174 participants reported 30% reduction in pain intensity 
and showed a proportion of the treatment group with high baseline pain reported 
significantly higher reduction in pain compared to placebo [81] (30% pain reduction: 
RR 0.19 95% CI 0.07 to 0.30, very low-quality, Analysis 2.1). However, when 
reporting mean pain intensity of the whole sample post-treatment, no significant 
effect was reported. A separate study by the same author group described a greater 
proportion of patients with undefined ‘improvement’ in pain for oral cannabis extract 
over 15 weeks, though this is difficult to interpret without understanding how the 
authors defined ‘improvement’.[80] 
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Secondary outcomes: One study reported mean sleep post-treatment and 
found no difference between groups.[81] No other outcomes were reported.  
We downgraded all outcomes for this comparison to very low due to the small 
number of participants contributing to analyses.  
 
3.3.3 CBM vs. control at short-term follow-up (up to 7 days treatment duration) 
Four trials studied the effects of single dose cannabinoids on acute post-
operative pain [34; 38; 54; 63] and two on cancer pain [32; 51] over the short term. A 
number of cannabinoids were delivered including a THC congener Benzopyran 
peridine,[32] a cannabinoid receptor agonist AZD1940 [34] and GW842166,[54] 
nabilone (a synthetic THC analog [38]) and two studies delivering different doses of 
THC (5- 20mg; [51; 63]). We analysed these studies together as there were too few 
data to analyse by CBM or cannabinoid type.  
Pain: One study including 105 participants with cancer reported 30% pain 
reduction [32] and two studies including 207 participants with cancer reported 50% 
pain reduction.[32; 51] Those studies delivered a THC congener or THC 
respectively. Neither analysis showed differences between cannabinoid and placebo 
(30% pain reduction: RR 0.11 95% CI -0.09 to 0.32, very low-quality, Analysis 3.1; 
50% pain reduction: RR 0.07 95% CI -0.29 to 0.43, very low-quality; Analysis 3.2). 
No trials of acute post-operative pain could be entered into analyses.  
We were unable to combine any other data for other outcomes across these 
studies. One three-arm study showed no difference between AZD1904 and placebo, 
but participants receiving naproxen reported a significantly lower pain intensity 
compared to placebo after the operation.[34] A second study also failed to show any 
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difference between GW842166 and placebo, and ibuprofen was superior to both at 
reducing pain intensity.[54] Oral THC and nabilone were also without effect.[38; 63] 
In conclusion, we found no analgesic effect for CBM in acute or cancer pain 
when treatment was delivered up to 7 days. 
Secondary outcomes: One study assessed mood and found no difference 
between groups on anxiety post-treatment.[34] 
Rescue medications were assessed in two acute pain studies.[34; 54] One 
study found that participants in the treatment group requested rescue medication 
later compared to placebo, but earlier compared to ibuprofen.[54] There was no 
difference between participants in the AZD1940 and placebo group requesting 
rescue medications.[34] However, people taking naproxen requested significantly 
fewer rescue medications compared to the other two groups.[34]   
We could not extract data for other outcomes. We downgraded all outcomes 
for this comparison to very low due to the small number of participants contributing to 
analyses, meaning we have very little confidence in the effect estimate; the true 
effect is likely to be substantially different from the estimate of effect.  
 
3.3.4 CBM vs. control at long-term follow-up (greater than or equal to 7 days 
treatment duration)  
We could combine data for nabiximols, THC, PEA and FAAH. Due to single 
studies delivering other types of cannabinoids, we did not combine data. Studies that 
did not include a minimum pain intensity are not included in these analyses. See 




We could extract data from 12 studies.[3; 16; 26; 33; 35; 39; 48; 49; 53; 57; 
59; 64] 
Pain: Six trials (1484 patients) have reported results for at least 30% pain 
relief compared with placebo in any pain condition.[33; 35; 53; 57; 59; 64] The 
combined effect was a small beneficial effect (RD 0.06, 95% CI 0.01 to 0.12, very 
low-quality evidence, Analysis 4.1.1). This would be equivalent to an NNTB of 17; 
the number of patients in nil effect trials required to reduce the effect to a clinically 
irrelevant NNTB of 20 would be 262. We downgraded this outcome twice for 
limitations in the design and implementation of available studies and once for 
indirectness of evidence.  
Two trials (464 participants) have reported results for at least 50% pain relief, 
showing no difference from placebo (RD 0.07, 95% CI -0.04 to 0.17; very low-quality 
of evidence, Analysis 4.2.1).[35; 53] We downgraded this outcome due to small 
number of participants contributing to the analyses.  
Only one study reported post-treatment means and standard deviations, and 
therefore we analysed mean change to be comprehensive.[59] Twelve studies (2497 
patients) reported mean pain change, showing a small benefit (Mean difference (MD) 
-0.34, 95% CI -0.54 to -0.14; very low-quality of evidence, Analysis 4.3.1).[3; 16; 26; 
33; 35; 39; 48; 49; 53; 57; 59; 64] We downgraded this outcome twice for limitations 
in the design and implementation of available studies and once for unexplained 
heterogeneity (50%).  
 Secondary outcomes: No studies reported post-treatment means and 
standard deviations for the secondary outcomes with the exception of quality of life. 
In one study, no differences between groups were found for quality of life 
outcomes.[33] Change score analyses were conducted for physical functioning, 
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emotional functioning, sleep and quality of life, no difference between groups was 
found with the exception of a significant improvement in sleep quality, favouring 
nabiximols. NCT01606176 reported a significant difference between the number of 
days using rescue analgesia, favouring the treatment group,[48] but six other trials 
reporting change scores found no difference between groups. 
 
3.3.4.2 THC 
Pain: We could include two trials (528 participants) in an analysis for at least 
30% pain relief compared with placebo in any pain condition.[2; 33] There was no 
beneficial effect (RD -0.02, 95% CI -0.09, 0.05; very low-quality of evidence, Analysis 
4.1.2). We downgraded this outcome to very low due to limitations in the design and 
implementation of available studies and indirectness of evidence. We did find any 
studies that reported 50% reduction of pain intensity.  
One study reported post-treatment means and standard deviations so we 
could not analyse data (no differences reported between groups).[38] For 
comprehension, we also analysed mean change and found four studies (795 
patients) have reported no beneficial effect of THC compared to control (MD -0.15, 
95% CI -0.48 to 0.17; very low-quality, Analysis 4.3.2).[2; 3; 33; 62] We downgraded 
twice for limitations in the design and implementation of available studies and once 
for selective reporting biases.  
Secondary outcomes: Two studies reported no difference in sleep quality 
between groups. No data could be extracted to assess other outcomes.  
 
3.3.4.3. PEA  
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Pain: Two trials (744 patients) have reported results for at least 30% pain 
relief compared with placebo in any pain condition. The combined effect showed no 
benefit of PEA compared to placebo (RD 0.21, 95% CI -0.37 to 0.80; very low-quality 
Analysis 4.1.3).[1; 22] We downgraded once for limitations in the design and 
implementation and twice for heterogeneity (98%). Two trials (704 patients) have 
reported results for at least 50% pain relief, with no beneficial effect of PEA 
compared to placebo (RD 0.17, 95% CI -0.23 to 0.57, very low-quality evidence, 
Analysis 4.2.3).[1; 22] We downgraded both outcomes once for limitations in the 
design and implementation and twice for heterogeneity (>95%).  
One study (78 participants) assessed post-treatment mean and standard 
deviations and did not find a beneficial effect of PEA compared to control.[15] Two 
studies (697 patients) reported mean pain change, showing no benefit (MD -0.95, 
95% CI -3.14 to 1.25, very low quality, Analysis 4.3.3).[15; 22] We downgraded once 
for limitations in the design and implementation twice for imprecision.  
Secondary outcomes: No other meta-analyses could be conducted. One 
study reported no differences between groups on physical functioning, emotional 
functioning, sleep, and quality of life.[1] 
 
3.3.4.4. FAAH inhibitors 
Pain: No studies reported 30% or 50% reduction of pain intensity. One study 
delivered FAAH inhibitor ASP3652 and reported post-treatment mean and standard 
deviations but no effect was found.[74] The same study (86 participants) reported 
mean change from baseline, and similarly, no beneficial effect was found between 
groups.[74] We downgraded both outcomes to very low due to small number of 
participants contributing to the analysis.  
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 Secondary outcomes: No data were extractable for the remaining outcomes.  
No other CBM reported results in more than two studies. 
 
3.3.5 Adverse events 
The following analyses included all studies delivering cannabis or relevant 
CBM regardless of treatment length.  
 
3.3.5.1 Cannabis 
Participants with adverse events: Two studies, (750 participants) reported 
participants with any adverse event (AEs) and reported no difference between 
groups (RD 0.08, 95% CI -0.10 to 0.25, very low-quality, Analysis 5.1.1). We 
downgraded this outcome once for limitations in the design and implementation and 
twice for heterogeneity (<95%). One study reported if participants experienced a 
treatment-related AEs and found a significantly higher number of people receiving 
cannabis reported AEs compared to those in the control group.[81] 
Participants with serious adverse events: Three studies (690 participants) 
reported no difference between groups on the number of people with serious 
adverse events (SAEs) overall (RD -0.05, 95% CI -0.16 to 0.07, very low-quality, 
Analysis 5.3.1). We downgraded this outcome once for limitations in the design and 
implementation and twice for heterogeneity (>75%). One study (120 participants) 
reported treatment-related SAEs and also found no difference between groups.  
Withdrawals: Two studies (605 participants) reported all causes of withdrawal, 
but no difference between groups was found (RD 0.05, 95% CI -0.03 to 0.13, very 
low-quality, Analysis 5.5.1). We downgraded this outcome once for limitations in the 
design and implementation, once for indirectness, and once for heterogeneity 
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(>50%). Two studies also reported withdrawals due to AEs in 605 participants, and 
no differences was found between groups (RD 0.08, 95% CI -0.08 to 0.25, very low-
quality, Analysis 5.6.1). We downgraded this outcome once for limitations in the 
design and implementation and twice for heterogeneity (<95%).  Just one study 
reported withdrawal due to lack of efficacy, and similarly no difference between 
groups was reported. No studies reported withdrawals due to SAEs.  
 
3.3.5.2 Nabiximols 
Participants with adverse events: Twelve studies (2551 participants) reported 
participants in the treatment group were more likely to have an AE compared to 
control (RD 0.13, 95% CI 0.08 to 0.19, low-quality evidence, Analysis 5.1.2). We 
downgraded this outcome twice for limitations in the design and implementation of 
included studies. Similarly, participants in the nabiximols group were significantly 
more likely to report a treatment-related AE compared to control (RD 0.19, 95% CI 
0.10 to 0.27, very low-quality, Analysis 5.2.2). We downgraded this outcome twice 
for limitations in the design and implementation of included studies and once for 
heterogeneity (>50%).  
Participants with serious adverse events: When investigating SAEs, we found 
no group differences in 11 studies (2108 participants; RD 0.02, 95% CI -0.00 to 0.04, 
low quality, Analysis 5.3.2). We downgraded this outcome twice for limitations in the 
design and implementation of included studies. Similarly, in five studies with 1418 
participants, no difference was found for treatment-related SAEs (RD 0.01, 95% CI -
0.02 to 0.04, very low-quality, Analysis 5.4.2). We downgraded this outcome twice 
for limitations in the design and implementation of included studies and once for 
heterogeneity (>50%).  
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Withdrawals: Eleven studies (2489 participants) reported all causes of 
withdrawals and no difference was found between groups (RD 0.03, 95% CI -0.01 to 
0.07, low-quality evidence, Analysis 5.5.2). We downgraded this outcome twice for 
limitations in the design and implementation of included studies. However, 
significantly more people withdrew from the treatment group due to AEs compared to 
control (12 studies, 2601 participants, RD 0.04, 95% CI 0.01 to 0.06, very low-
quality, Analysis 5.6.2). We downgraded twice for limitations in the design and 
implementation of included studies and once for unexplained heterogeneity (>50%).  
When investigating withdrawals due to lack of efficacy (9 studies, 2001 participants) 
and due to SAE (5 studies, 729 participants), we did not find differences between 
groups (RD -0.01, 95% CI -0.02 to 0.00, Analysis 5.7.2; RD 0.00, 95% CI -0.01 to 
0.02, Analysis, 5.8.1, respectively). We rated both as low-quality evidence. We 
downgraded the former twice for limitations in the design and implementation of 
included studies and the latter once for limitations in the design and implementation 
of included studies and once for indirectness.  
 
3.3.5.3 THC 
Participants with adverse events: We found participants in the THC arm 
reported more AEs compared to the control arm in four studies with 1168 
participants (RD 0.15, 95% CI 0.05 to 0.24, very low-quality, Analysis 5.1.3). We 
downgraded this outcome once for unexplained heterogeneity (>50%) and twice for 
selective reporting biases. Only one study with 240 participants reported treatment-
related AEs, which were significantly higher in the treatment compared to control 
group.  
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Participants with serious adverse events: Five studies reported SAEs (1012 
participants) and one study reported treatment-related SAEs (240 participants). We 
found both analyses showed no difference between treatment and control groups 
(RD 0.00, 95% CI -0.02 to 0.02, low-quality, Analysis 5.3.3; RD 0.01, 95% CI -0.01 to 
0.03, very low-quality, Analysis 5.4.3, respectively). We downgraded the former once 
for limitations in the design and implementation of included studies and once for 
selective reporting bias, and the latter to very low due to the small number of 
participants able to be included in the analysis.  
Withdrawals: We found six studies (1357 participants) reported all causes of 
withdrawals, and no difference between groups was found (RD 0.01, 95% CI -0.06 to 
0.08, very low-quality, Analysis 5.5.3). We downgraded once for limitations in the 
design and implementation of included studies and twice for heterogeneity. We 
found no differences between groups when investigating withdrawals due to AEs (7 
studies, 1428 participants, RD 0.02, 95% CI -0.01 to 0.05, very low quality, Analysis 
5.6.3), SAEs (4 studies, 979 participants, RD 0.00, 95% CI -0.01 to 0.01, low-quality, 
Analysis 5.8.2), or lack of efficacy (3 studies, 675 participants, RD 0.00, 95% CI -
0.01 to 0.01, very low-quality, Analysis 5.7.3).  
We downgraded withdrawals due to AEs twice for heterogeneity and once for 
selective reporting bias. We downgraded withdrawals due to SAEs once for 
indirectness and once for selective reporting bias. We downgraded withdrawals due 
to lack of efficacy once for limitations in the design and implementation of included 




Participants with adverse events: We analysed three studies (770 
participants) who reported any adverse event and found no differences between 
groups (RD 0.03, 95% CI -0.07 to 0.14, very low-quality, Analysis 5.1.4). We 
downgraded once for or limitations in the design and implementation of included 
studies and twice for heterogeneity.  No studies reported treatment-related AEs.  
Participants with serious adverse events: We analysed three studies (770 
participants) who reported SAEs and treatment-related SAEs and found no 
differences between groups for either outcomes (RD 0.02, 95% CI -0.05 to 0.08, very 
low-quality, Analysis 5.3.4; RD 0.00, 95% CI -0.01 to 0.01, low quality, Analysis 
5.4.4). We downgraded the former outcome once for limitations in the design and 
implementation of included studies and twice for heterogeneity and the later outcome 
once for limitations in the design and implementation of included studies and once 
for indirectness.  
Withdrawals: We analysed three studies (770 participants) who presented 
data for withdrawals and found no differences between groups (RD -0.03, 95% CI -
0.07 to 0.01, low-quality evidence, Analysis 5.5.4). We downgraded this outcome 
once for limitations in the design and implementation of included studies and once 
for indirectness.  
We could not run a meta-analysis for withdrawals due to AEs or SAEs as only 
one study with 73 participants reported this data. This study indicated no differences 
between groups. No study reported withdrawal due to lack of efficacy.  
 
3.3.5.5 FAAH inhibitors 
Participants with adverse events: A single study (238 participants) could be 
included when assessing participants with adverse events and treatment-related 
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adverse events, and there was no difference between groups in either analysis. A 
second EERW study reported adverse events but we did not combine data due to 
the different study types.[4] 
Participants with serious adverse events: One EERW study reported one SAE 
in each group and no SAEs in either group relating to treatment.[4] A further study 
reported no differences for participants experiencing treatment-related SAEs.[74] 
The data were not combined in an analysis due to different study designs.   
Withdrawals: We found two studies with different study designs report on 
withdrawals, but we did not combine the data. No differences were found for all 
causes of withdrawals. One study reported withdrawals due to AEs and found more 
people withdrew in the treatment compared to the control group. We could not 
extract any data for other withdrawal outcomes.  
 
3.3.5.6 Cannabinoid receptor agonists 
Participants with adverse events: One study (123 participants) reported any 
AEs and indicated no differences between groups. No studies reported AEs related 
to treatment.  
Participants with serious adverse events: We found two studies (274 
participants) reported any participants with an SAE. The analysis did not show any 
differences between groups (RD -0.04, 95% CI -0.22 to 0.15, very low-quality, 
Analysis 6.3.4). We downgraded this outcome to very low due to small number of 
participants that could be included in the analysis. No studies reported treatment-
related SAEs.  
 Withdrawals: We found two studies (274 participants) reported all causes of 
withdrawal, withdrawals due to AEs and withdrawals due to SAEs. For all analyses, 
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no differences could be found between groups (RD 0.01, 95% -0.02 to 0.04, Analysis 
5.5.6; RD 0.00, 95% CI -0.02 to 0.02, Analysis 5.6.6; RD 0.00, 95% CI -0.02 to 0.02, 
Analysis 6.8.6 respectively). We rated all three outcomes as very low-quality 
evidence due to the small number of participants that could be included in the 
analysis.  On study reported withdrawals due to lack of efficacy and did not indicate 
any difference between groups.  
 
3.3.6 Subgroup analyses 
We analysed studies by pain condition type, irrespective of drug, dose, or 
route of administration; Figure 4 shows results for 30% pain intensity reduction, 
Figure 5 shows 50% pain intensity reduction, and Figure 6 shows mean difference 
(on a 0-10 scale). A description and forest plots relating to secondary outcomes can 
be found in Appendix 8.  
 
3.3.6.1 Acute pain 
Four trials studied the effects of single dose cannabinoids on acute pain over 
the short term, three on postoperative pain,[34; 54; 63] and one studied 
postoperative nausea and vomiting [38]. We did not find any other acute pain 
studies, and no data from these studies could be combined into a meta-analysis. 
See section 3.3.3 for a description of the results.  
 
3.3.6.2 Cancer pain 
Two trials studied the effects of THC congener or THC for cancer pain over 6 
hours. [32; 51] Five trials (four studies) studied the effects of cannabinoids on cancer 
pain over 2 to 5 weeks, all using nabiximols. Four studies delivered nabiximols,[16; 
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33; 39; 57] one study also delivered THC alone.[33]  Five of these studies had a 
minimum pain intensity of 4/10, so should have had sufficient sensitivity to detect a 
difference. 
Pain: Pain outcomes for the two trials delivering treatment over 6 hours to 
participants with cancer pain are described in section 3.3.3. 
Two trials delivering treatment 2-5 weeks;[33; 57] 477 participants) reported at 
least 30% pain relief, however, no benefit of cannabinoids were identified for 
reducing pain compared to placebo (RD 0.09, 95% CI -0.06 to 0.23, very low-quality, 
Analysis 6.1.2). We rated this outcome as very low-quality evidence due to the small 
number of participants that could be included in the analysis. No studies reported 
50% pain reduction or pain intensity post-treatment.  
Instead, four studies reported mean change from baseline (1259 participants) 
and findings showed no benefit of nabiximols compared to placebo (MD on a 0-10 
scale -0.22, 95% CI -0.49 to 0.06, very low-quality Analysis 6.3.1;[16; 33; 39; 57]). 
We downgraded twice for limitations in the design and implementation of included 
studies and once for unexplained heterogeneity (>50%).  
The second study from Fallon et al., [16] was an enriched enrolment 
randomised withdrawal study that found no difference between nabiximols and 
placebo. 
Secondary outcomes: No data could be combined in an analysis for remaining 
outcomes. Change from baseline was reported for emotional functioning, sleep and 
quality of life but no differences were found in favour of CBM and declines in 
cognitive functioning and nausea were reported in two studies in the treatment 
groups.  
These findings show no analgesic effect for CBM in cancer pain. 
 34 
 
3.3.6.3 Neuropathic pain, less than 1-day cannabinoid treatment duration 
The results for three trials [76-78] evaluated the effects of inhaled or 
vaporised cannabis (THC) on chronic neuropathic pain in single dose experiments 
lasting one day or less and are described in 3.3.1.  
 
3.3.6.4 Neuropathic pain studies less than 4 weeks’ treatment duration 
Two studies delivered nabiximols to participants with neuropathic pain lasting 
one day to four weeks but did not provide data for our primary analyses.[3; 48] Both 
studies had a minimum pain intensity of 4/10 and should have sufficient sensitivity to 
detect a difference. 
One study conducted a three-way crossover of nabiximols, THC, and placebo, 
with pain measured over the last week of a two-week treatment phase in 48 patients 
with brachial plexus avulsion.[3] There was a small but statistically significant 
reduction in mean pain score compared with placebo, with an implied 10% more 
patients achieving at least 30% pain intensity reduction. NCT01606176 [48] was a 
three-week trial of nabiximols in 70 patients with chronic refractory pain of 
neurological origin.[48] Both studies presented change scores and a difference 
between groups was found (MD -0.55, 95% CI -0.93 to -0.17, very low-quality, 
Analysis 6.3.2). We downgraded to very low-quality due to the small number of 
participants in the analysis.  
No convincing analgesic effect was found for CBM in neuropathic pain in 
studies less than 4 weeks’ duration. 
Secondary outcomes: No data could be combined in an analysis for remaining 
outcomes. NCT01606176 reported a significant difference between the number of 
 35 
days using rescue analgesia, favouring the treatment group.[48] Change data did not 
show any notable differences between groups.  
 
3.3.6.5 Neuropathic pain studies; more than 4 weeks’ cannabinoid treatment 
duration 
Eight studies lasting longer than five to 15 weeks evaluated the effects of 
CBM in neuropathic pain (neuropathic pain in multiple sclerosis is handled 
separately). Of the eight studies, five delivered nabiximols, and one each delivered 
nabilone, PEA, or an FAAH-1 inhibitor. All studies had a minimum pain intensity of 
4/10 and therefore should have sufficient sensitivity to detect a difference. 
Pain: Four trials (736 participants) reported 30% pain reduction post-
treatment. We found no difference between treatment and placebo groups (RD 0.03, 
95% CI -0.07 to 0.12, low-quality, Analysis 6.1.5).[1; 26; 53; 64] We downgraded 
once for limitations in the design and implementation of included studies and once 
for unexplained heterogeneity. Similarly, in two trials (193 participants) that reported 
50% reduction in pain intensity, we found no difference between treatment and 
control groups (RD 0.05, 95% CI -0.11 to 0.21, very-low quality, Analysis 5.2.5) [1; 
53]. We downgraded this outcome to very low due to the small number of 
participants contributing to the analysis.  
Only one study reported end of treatment means and standard deviations for 
pain intensity and showed no difference between groups.[1] Therefore, for 
comprehension, we extracted mean change data from baseline, reported by five 
studies (768 patients). We found no significant change in pain between treatment 
groups (MD -0.31, 95% CI -0.65 to 0.03, low-quality, Analysis 6.3.3).[1; 26; 49; 53; 
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64] We downgraded this outcome once for limitations in the design and 
implementation of included studies and once for selective reporting bias.  
Two studies did not provide data for analysis. One study compared nabilone 
with dihydrocodeine in 96 patients with chronic neuropathic pain in a crossover study 
and found dihydrocodeine to be significantly better.[20] A separate study reported no 
difference in reduction of pain between groups.[25] 
A further study  used an enriched enrolment randomised withdrawal design 
lasting longer than four weeks in total, and with a three-week randomised withdrawal 
phase.[4] Due to the different study design, we describe these findings separately. 
The authors compared FAAH inhibitor with placebo. Of the 132 patients with 
peripheral neuropathic pain entering the initial phase, 71 entered the randomised 
withdrawal phase; there was no difference between active drug and placebo. 
No convincing analgesic effect was found for CBM in neuropathic pain in 
studies longer than 4 weeks. 
Secondary outcomes: No other meta-analyses could be conducted. One 
study reported no differences between groups on physical functioning, emotional 
functioning, sleep, and quality of life.[1] The same study reported a significantly 
larger number of participants in the PEA groups consumed rescue analgesia 
compared to the control group.[1] However, change analyses from four studies 
showed better sleep in participants in the treatment group compared to control, but 
no other analyses could be conducted.  
 
3.3.6.6 Multiple sclerosis related chronic pain: CBM studies longer than 4 
weeks 
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Three studies lasting five to 14 weeks examined the effects of CBM, 
specifically for chronic pain associated with MS.[35; 59; 62] Two studies had a 
minimum pain on entry of 40% of maximum, and all had mean initial pain scores of 
65% of maximum or greater, so should have had sufficient sensitivity to detect a 
difference. Two used nabiximols, and one dronabinol and all compared to placebo 
control. 
Pain: One study studied 339 patients taking nabiximols or placebo for 14 
weeks, and provided the proportions achieving at least 30% and 50% pain intensity 
reduction; neither showed a benefit of nabiximols compared to placebo (Analysis 
5.1.6 and 5.2.6).[35] 
One study reported end of treatment means and standard deviations and 
showed a significant reduction in pain intensity for the treatment compared to 
control.[59] All three studies (613 patients) provided mean change in pain scores, 
and we found no difference between CBM and placebo (MD -0.41, 95% CI -1.02 to 
0.19, very low-quality, Analysis 6.3.4).[35; 59; 62] We downgraded once due to 
unexplained heterogeneity and twice for selective reporting bias.  
No convincing analgesic effect was found for CBM in neuropathic pain 
associated with multiple sclerosis in studies longer than 4 weeks. 
Secondary outcomes: No data could be extracted for the remaining outcomes.   
 
3.3.6.7 Multiple sclerosis studies principally examining CBM for spasticity 
Six studies lasting less than one day to 15 weeks examined the effects of 
CBM in MS and reported some pain measures. None had a minimum pain 
requirement at baseline, two reported initial pain at baseline (15% and 55% of 
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maximum.[6; 40] Three delivered nabiximols [5; 37; 40] and three delivered cannabis 
extract (all with THC; [6; 80; 81]). All studies compared to placebo control.  
Pain: One study with 174 participants reported 30% reduction in pain intensity 
and showed the treatment group reported significantly higher reduction in pain 
compared to placebo (Analysis 6.1.7).[81] Another study reported that 76% (n = 37) 
of patients with a ≥30% spasticity response also reported ≥30% reduction in pain 
intensity (but did not provide numbers for the placebo group).[5] A third study 
described a greater proportion of patients with undefined ‘improvement’ in pain for 
oral cannabis extract over 15 weeks, though this is difficult to interpret without 
understanding how the authors defined ‘improvement’.[80] 
When extracting mean pain intensity post-treatment, two studies with 337 
participants [6; 81] reported no significant difference between groups. 
One study found no difference between nabiximols and placebo for pain in a 
four-week crossover study.[37] A further study reported results of an enriched 
enrolment study in 107 patients over 12 weeks; mean pain was significantly lower 
with nabiximols than placebo.[40] 
There is some evidence that CBM used to treat spasticity in multiple sclerosis 
also reduces pain, and there is a possibility that the two effects are linked.  
 Disability: In an enriched enrolment trial, no difference was found between 
groups for activities of daily living [40].  
 Emotional functioning: One study used the Brief Symptom Inventory and 
found no difference between groups post-treatment.[6] Another study also reported 
the SF-36 and reported no significant differences between groups on the mental 
health subscale at the end of treatment.[40] 
Secondary outcomes: No other meta-analyses could be conducted. 
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3.3.6.8 Multiple sclerosis progression 
A single study evaluated the effects of THC on slowing progression in 363 MS 
patients over three years.[2] 
Pain: There was no significant difference in mean pain/discomfort measured 
by the Multiple Sclerosis Spasticity Scale-88 at any time during the study, or in the 
proportion feeling significantly better at the end of the study. No other outcomes 
were assessed.  
Physical functioning: The study also reported the SF-36 “physical health” 
subscale but no differences were reported between groups throughout the study.  
Secondary outcomes: No other meta-analyses could be conducted. 
 
3.3.6.9 Pelvic pain 
A single study examined the effects of a FAAH inhibitor to placebo on 226 
participants with chronic prostatitis or pelvic pain over 12 weeks.[74] There was no 
minimum inclusion criteria regarding minimum reported pain intensity.  
Pain: One study reported no significant differences between ASP3652 and 
placebo on pain intensity.[74] 
Quality of life: Similarly, no differences between treatment and control were 
reported for quality of life outcomes.[74] 
Secondary outcomes: No other meta-analyses could be conducted. 
 
3.3.6.10 Carpal tunnel syndrome 
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A single study examined the effects of oral PEA to placebo in 61 patients with 
carpal tunnel syndrome over eight weeks.[15] There was no minimum inclusion 
criteria regarding minimum reported pain intensity.  
Pain: There was no significant difference between PEA and placebo.  
Physical functioning: There was no significant difference between PEA and 
placebo. 
Secondary outcomes: No other meta-analyses could be conducted. 
 
3.3.6.11 Low back pain 
A single study examined the effects of oral PEA 300 mg or 600 mg in 676 
patients with low back pain-sciatica, defined as “lumbosciatic algias” over three 
weeks,[22] with additional analyses [8]). Participants had to report a minimum pain 
intensity of 5/10 or equivalent to be included in the study.  
Pain intensity: This study reported 50% reduction in pain intensity showing 
considerable benefit over placebo (Analyses 6.3.8).[22] The proportion with at least 
50% pain intensity reduction with placebo was 22%, and with PEA was 58%; there 
was an obvious dose response, with much larger benefit with 600 mg daily. There 
was also a much greater reduction in average pain score with PEA (both doses 
combined) than placebo, again with a greater effect with 600 mg. We rated both 
outcomes as very low-quality as they only included one study, had limitations in the 
design and implementation of available studies. 
This is a significant result in a large number of patients. 
 Physical functioning: Physical functioning was also increased in those 
participants in the treatment group compared to the control group. The authors found 
 41 
63% of participants improved their physical functioning score in the treatment group 
compared to 22% in the control group.[22]  
Secondary outcomes: No other meta-analyses could be conducted. 
 
3.3.7 Potential impact of exclusion of small studies 
 Thirty-nine studies (794 patients given cannabinoids, cannabis, or CBM, 
mean 20 per trial, median 21 per trial) were excluded because of small size, 
potentially adding 108% additional trials but only 13% additional patients completing 
trials. Appendix 4 provides an analysis and details of the small excluded studies. 
These studies involved 12 different types of cannabis, cannabinoid or CBM in 18 
different pain conditions, mostly (22/39) crossover studies. The majority (69%) used 
the oral route of administration, with 5 sublingual, 3 smoked, 2 inhaled, and 2 
intramuscular injections. Eleven were single dose studies with duration less than one 
day and a further 10 lasted 1 to 14 days. There was variable reporting of outcomes. 
 Of the 39 trials, 22 claimed no effect of cannabis, cannabinoid or CBM, while 
17 claimed some statistical benefit. Because of the small numbers potentially added 
to any analyses and very considerable clinical heterogeneity, the results of the main 
analyses in this review could not materially be altered by adding the small studies. 
 
Discussion  
 This review of RCTs forms part of a wider programme of work requested by 
the International Association for the Study of Pain Presidential Task Force on 
Cannabis and Cannabinoid Analgesia. We aimed to summarise the evidence of 
cannabinoids, cannabis and CBM for people with pain, examining the efficacy and 
adverse events reported in trials. We found 36 trials, with 7217 participants 
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randomized to treatment that ranged from a day to 15 weeks. Most studies 
investigated people with neuropathic pain or included people with pain associated 
with multiple sclerosis, but we also found studies investigating other pain conditions 
including acute post-surgical pain, cancer pain, back pain, carpal tunnel, and pelvic 
pain. 
 No study was rated as low risk of bias across all risk of bias domains; studies 
were rated as having unclear or high risk of bias in at least one domain, and typically 
in several domains. Risks of bias, high heterogeneity in some analyses, and the 
likelihood of selective reporting biases influenced our judgements of the quality of 
evidence. No outcomes achieved a higher than ‘low-quality’ rating. In fact, we rated 
most outcomes as very low-quality of evidence, meaning we are very uncertain of 
the estimates of effect reported. 
We analyzed the efficacy of delivering cannabis (as opposed to individual 
cannabinoids or CBM) to people with pain and found a limited number of studies 
providing evidence. When assessing the effect of cannabis delivered for <1 week, 
two studies (231 participants) found a beneficial effect for patients undergoing 
surgery (very low-quality evidence). Only one study reported extractable data for 
cannabis delivered for >1 week, which indicated a beneficial effect of cannabis 
compared to control. We did not find any trials delivering cannabis for people with 
chronic pain that met our inclusion criteria. We found limited evidence for adverse 
events (1-3 studies contributing to each analysis). We found no difference between 
group for the adverse events analyses with the exception of treatment-related 
adverse events, where people in the cannabis group reported more AEs compared 
to the control. We found no differences for withdrawals between groups.  
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 We found six studies that delivered CBM (including cannabinoids) to people 
with pain for a treatment duration of <1 week but could only extract data from two or 
fewer when analyzing outcomes. We did not find beneficial effects for reducing any 
pain intensity outcome.   
We found more evidence for CBM; specifically for nabiximols delivered for >1 
week treatment duration. Nabiximols showed small beneficial effects for 30% 
reduction in pain intensity and change in pain intensity scores (both outcomes very 
low-quality). THC, PEA, and FAAH inhibitors did not show beneficial effects 
compared to control in our primary analyses. When analyzing our secondary 
outcomes, we could only combine change score data for nabiximols and THC. 
Nabiximols showed beneficial effects for improving physical functioning in four 
studies and sleep quality in 13 studies. Nabiximols did not show beneficial effects for 
emotional functioning or quality of life, and two studies delivering THC did not show 
beneficial effects for sleep quality (data could not be extracted for other secondary 
outcomes).  
 We also analyzed studies by pain condition type and found no beneficial 
effects in favour of cannabinoids, cannabis or CBM for participants with acute pain, 
cancer-related pain, multiple sclerosis; we could not combine data for conditions 
including pelvic pain, carpal tunnel syndrome, or low back pain. We found a small 
benefit at reducing pain in neuropathic pain (<7 days) in two studies (very low-
quality), and pain change scores for neuropathic pain (>4 weeks) in five studies (low 
quality) were undermined by the small size of the benefit and the likelihood of 
residual positive bias in the studies. Benefits of CBM (including the THC studies that 
did not show an improvement in sleep) were also found for improving sleep quality 
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for neuropathic pain of both less than and more than 4-week treatment duration 
(both very low-quality), although similar caveats apply.  
The current available evidence provides us with no confidence that a defined 
cannabinoid, cannabis or CBM product, at a defined dose, using a defined route of 
administration, reduces pain intensity in any condition. Nor do we fully understand 
the long-term implications of taking cannabinoids, cannabis and CBM. Evidence is 
emerging on the negative long-term effects of cannabis, in particular cannabis with 
high THC content (>10% potency; [11]) but data for longer-term use of cannabinoids, 
cannabis, and CBM in a medicinal context are lacking at present. A separate work 
package has investigated the adverse effects of cannabis and CBM[21] and there is 
a distinct underreporting of adverse events in this field.[43; 68; 69] We found adverse 
events to be higher in nabiximols and THC treatment groups compared to control.  
As is usual with systematic reviews of clinical trial evidence, we attempted to 
extract means and standard deviations post-treatment. These data are preferable to 
change scores, as successful randomization will result in no group baseline 
differences and therefore means/SDs can be compared at post-treatment to 
determine the efficacy of a treatment. However, it was not possible to extract means 
and standard deviations from the included studies, and when we requested data 
from authors, we received very few responses. Whilst one author provided partial 
data, and another fully responded to our request, pharmaceutical companies stated 
they could not provide post-treatment means and standard deviations. The lack of 
openness and transparency is against current best practice in science [50] 
and can lead one to question why data are being withheld. For the 
comprehensiveness of our review, we analyzed available change score data and 
found very few beneficial effects of cannabis or CBM.  
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 There are still many missing areas of understanding within the evidence base, 
due to poorly reported trials and lack of exploration in this area. For example, we 
could not extract any caregiver global impression of change across the included 
studies. There were also very few studies reporting on the effect of physical and 
emotional functioning, although sleep was more consistently reported across studies.  
For transparency we have described the small n studies excluded by our 
protocol (12 cannabinoids, cannabis, and CBM studies, 18 pain conditions, 5 routes 
of administration, variation in study duration of <1 to 84 days, and limitations in 
outcomes reported). The conclusions of the main analyses in this review could not 
be affected by adding the small studies.  A recent systematic review reported larger 
effect sizes and higher uncertainty in studies with fewer than 30 participants/arm.[72] 
Higher effect sizes with small size is a recognized problem in systematic reviews, 
including systematic reviews of pain treatments.[10; 17; 44; 52] 
This systematic review should be interpreted alongside the overview review of 
cannabinoids, cannabis and CBM.[47] That overview found 57 systematic reviews 
analyzing cannabis and CBMs. Those reviews were rated for quality using several 
indicators; the authors rated 41 as critically low, eight low quality, six as moderate, 
and two as high quality. Twenty-five reviews presented positive recommendations in 
the abstract, 12 reviews had negative recommendations, seven held equipoise, and 
13 state no recommendations for or against cannabinoid, cannabis, or CBMs. We 
believe that this review addresses the requirements of AMSTAR-2 [65] and the 
critical pain criteria suggested by Moore et al [47] as far as the available trial reports 
allow. 
Implications for research: There are many avenues for future research in this 
field. First, compared with the diversity of cannabinoids assessed preclinically, very 
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few have been investigated in clinical trials in pain, and better understanding of the 
analgesic effects of different compounds is needed, including both plant-derived and 
synthetic modulators of the endocannabinoid system. Thus, research on other 
cannabinoids where we did not identify any studies here, such as cannabidiol, could 
be explored to determine if they have any analgesic properties. Second, research 
should not be restricted to Western, educated, industrialized, rich, democratic 
(WEIRD) countries [28] and in small sample sizes. All studies came from WEIRD 
countries and only two studies in our review included more than 200 participants/arm 
and were rated as ‘low risk of bias’ for size. Third, coordinated, double blind, 
multicenter studies that include people with a minimum pain intensity of 4/10 should 
be carefully designed and conducted for well-defined pain conditions and at well-
defined doses and routes of administration over long treatment periods. Rigorous 
reporting of these trials is critical to increasing the quality of evidence and confidence 
in the estimates of effect. Trial sponsors should register protocols, adhere to 
registered protocols, and make data available for scrutiny. Fourth, studies that 
investigate PK/PD relationships are essential. 
 Implications for practice: Currently, there is no evidence from RCTs to inform 
the practice of treating chronic pain patients with cannabinoids, cannabis or CBM to 
alter pain intensity, disability, emotional distress, or sleep. Although other, lower 
quality forms of evidence (e.g., non-randomised trials, case studies) are available 
analysing the beneficial and harmful effects of cannabis, cannabinoids, and CBM, 
these should be interpreted with caution as they are highly susceptible to bias and 
cannot provide a reliable evidence-base on which to translate into practice.  
In conclusion, the RCT evidence base for using cannabinoids, cannabis and 
CBM is of low or very low quality, and we found very few beneficial effects of the 
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drugs or strains that have been tested to date for people with pain. As with any 
known analgesic, it is unlikely that cannabinoids, cannabis or CBM will reduce pain 
for everyone. However, they may work for a small number of people, under the close 
supervision of specialists. High quality trials of other cannabinoids or CBM that have 






Changes to protocol: We combined 30% reduction in pain intensity and 
moderate improvement in pain intensity, and 50% reduction in pain intensity and 
substantial pain improvement in the methods. Both these assessments report the 
same outcome. We added the risk of bias domain ‘size’ to the review, which was not 
outlined in the protocol. We chose to do this due to the risk of bias of smaller studies 
in analyses. For transparency and comprehensiveness, to allow easy access to a 
summary, we extracted and reported mean change scores in Appendix 6, and we 
extracted and reported data but did not analyse them from studies with n<30 in 
Appendix 4. 
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Figure Legends 
Figure 1. PRISMA flow chart of studies 
Figure 2. Risk of bias 
Figure 3. Risk of bias summary  
Figure 4. Analysis 6.1. 30% reduction in pain intensity  
Figure 5. Analysis 6.2. 50% reduction in pain intensity 
Figure 6. Analysis 6.3. Mean change for pain intensity (0-10 rating scale) 
 
